title: Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
abstract: Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.
authors.affiliation: Institute of Molecular Medicine, Nuffield Department of Medicine, Oxford OX3 9DS, United Kingdom.
authors.forename: G S
authors.initials: GS
authors.lastname: Ogg
authors.forename: X
authors.initials: X
authors.lastname: Jin
authors.forename: S
authors.initials: S
authors.lastname: Bonhoeffer
authors.forename: P
authors.initials: P
authors.lastname: Moss
authors.forename: M A
authors.initials: MA
authors.lastname: Nowak
authors.forename: S
authors.initials: S
authors.lastname: Monard
authors.forename: J P
authors.initials: JP
authors.lastname: Segal
authors.forename: Y
authors.initials: Y
authors.lastname: Cao
authors.forename: S L
authors.initials: SL
authors.lastname: Rowland-Jones
authors.forename: A
authors.initials: A
authors.lastname: Hurley
authors.forename: M
authors.initials: M
authors.lastname: Markowitz
authors.forename: D D
authors.initials: DD
authors.lastname: Ho
authors.forename: A J
authors.initials: AJ
authors.lastname: McMichael
authors.forename: D F
authors.initials: DF
authors.lastname: Nixon
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis; D004359:Drug Therapy, Combination; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000032:analysis; D013602:T-Lymphocytes, Cytotoxic / Q000502:physiology*
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D000943:Antigens, Differentiation; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1